TURNING THE TIDE: BRAF-TARGETED THERAPY ENABLING SURGICAL DOWNSTAGING IN STAGE IVC ANAPLASTIC THYROID CANCER
Anaplastic thyroid cancer (ATC) constitutes less than 2% of thyroid cancer but accounts for up to 50% of thyroid cancer mortality, with a median survival of 3–6 months. All ATC is Stage IV at diagnosis by definition. BRAF V600E-mutant disease is the only molecularly defined subset with FDA-approved targeted therapy...